Identification and evaluation of novel prognostic genetic markers for childhood acute lymphoblastic leukemia by Ivanov Öfverholm, Ingegerd
From the DEPARTMENT OF MOLECULAR MEDICINE AND 
SURGERY 
Karolinska Institutet, Stockholm, Sweden 
IDENTIFICATION AND EVALUATION OF 
NOVEL PROGNOSTIC GENETIC 
MARKERS FOR CHILDHOOD ACUTE 
LYMPHOBLASTIC LEUKEMIA 
Ingegerd Ivanov Öfverholm 
 
Stockholm 2017 
 
 Cover and book art by Louise Brattström Stolt 
Illustrations and figures by Ingegerd Ivanov Öfverholm et al.  
 
All previously published papers were reproduced with permission from the publisher. 
Published by Karolinska Institutet. 
Printed by Eprint AB 2017  
© Ingegerd Ivanov Öfverholm, 2017  
ISBN 978-91-7676-621-7 
  3 
IDENTIFICATION AND EVALUATION OF NOVEL 
PROGNOSTIC GENETIC MARKERS FOR CHILDHOOD 
ACUTE LYMPHOBLASTIC LEUKEMIA 
 
THESIS FOR DOCTORAL DEGREE (Ph.D.) 
By 
Ingegerd Ivanov Öfverholm 
Principal Supervisor: 
Associate professor Gisela Barbany 
Karolinska Institutet 
Department of Molecular Medicine and Surgery  
 
Co-supervisor(s): 
Professor Magnus Nordenskjöld 
Karolinska Institutet 
Department of Molecular Medicine and Surgery  
 
Professor Ann Nordgren 
Karolinska Institutet 
Department of Molecular Medicine and Surgery  
 
Associate professor Mats Heyman 
Karolinska Institutet 
Department of Women’s and Children’s health 
 
Opponent: 
Professor Shai Izraeli 
Tel Aviv University 
Department of Human Molecular Genetics and 
Biochemistry  
 
Examination Board: 
Associate professor Johanna Ungerstedt 
Karolinska Institutet 
Department of Medicine Huddinge 
 
Associate professor Larry Mansouri 
Uppsala Universitet 
Department of Immunology, Genetics and 
Pathology 
 
Associate professor Catharina Lavebratt 
Karolinska Institutet 
Department of Molecular Medicine and Surgery   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 4 
 
 
 
 
It's not what you look at that matters,  
it's what you see.  
 
 
Henry David Thoreau 
.  
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ABSTRACT 
Childhood acute lymphoblastic leukemia (ALL) is the most common form of childhood 
cancer today. Due to advances in risk stratification and treatment, survival rates have 
increased drastically the last decades. Currently, children with acute leukemia in the Nordic 
countries are diagnosed and treated according to the NOPHO-2008 treatment protocol. In this 
protocol, a number of cytogenetic markers are used for risk stratification and guidance of 
treatment intensity. However, genetic markers associated with high risk are infrequent and 
relapses occur across all genetic subtypes, including those associated with a favorable 
outcome. Importantly, over 25% of childhood ALL cases harbor none of the currently used 
genetic risk markers in their bone marrow cells at diagnosis.  
The aim of this thesis was to generate a greater understanding of the genetic landscape in 
ALL, as well as to identify novel genetic markers of prognostic relevance, with special focus 
on the group of patients lacking risk-stratifying markers.  
In paper I, we investigated the frequency and prognostic impact of IKZF1 deletions in 
patients diagnosed with B-cell precursor (BCP) ALL in the Stockholm region; IKZF1 
deletions were present in 15% of cases and significantly associated with inferior outcome. 
These results led to paper II, where the cohort was extended to include BCP ALL cases with 
available IKZF1 data from other centers in Sweden. This study verified that IKZF1 deletion 
was an independent risk factor for decreased survival, and could confirm that the frequency 
and prognostic effect was most pronounced in patients without risk-stratifying markers.  
A high frequency of IKZF1 deletions could also be detected in paper III, where we 
investigated the genetic copy number landscape of BCP ALL across the different cytogenetic 
subtypes. This study showed that a majority of cases without risk-stratifying markers harbor 
deletions with potential prognostic significance, suggesting that a large proportion of this 
group could be assigned to distinct genetic subtypes. 
Intrachromosomal amplification of chromosome 21 (iAMP21) is an intermediate/high-risk 
subtype for which the biological cause of the high relapse risk is unknown. In paper IV, we 
used an integrated molecular approach to investigate the iAMP21 subtype, and identified 
significant overexpression of tree potential candidate genes, i.e. DYRK1A, SON and 
CHAF1B, with leukemia-relevant functions that could represent future targets for therapy. 
 
Together, these studies have identified a number of potential novel prognostic genetic 
markers that may contribute to the clinical risk-evaluation of children diagnosed with BCP 
ALL, and to our understanding of the biology behind relapse and poor outcome in this 
disease.  
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1 INTRODUCTION 
Leukemia is a malignant disease of the bone marrow, characterized by pathogenic growth of 
immature white blood cells. The term Leukemia, formed by the two Greek words “leukos” 
and “haima”, meaning “white” and “blood”, was introduced in 1847 by professor Rudolf 
Virchow, who observed an excess of white or colorless cells in the blood sample of a patient 
showing symptoms of spleen enlargement, bleeding and fever.1 
Ever since the discovery of the Philadelphia chromosome in 1960,2 much attention has been 
focused on the genetic events underlying leukemic transformation. Today, detection of 
genetic aberrations in diagnostic bone marrow samples is standard of care for most leukemia 
types, as it provides important diagnostic, prognostic and treatment-related information.  
 
1.1 THE GENETICS OF CANCER  
Cancer occurs when genetic mutations or rearrangements disrupt the normal machinery of the 
cell, causing potentially unlimited cell proliferation and expansion. Many cancers start with 
one or a few mutations with growth promoting properties; the rapid cell division rate, often in 
combination with impaired DNA repair mechanisms, results in new mutations, and different 
subclones emerge.3-6 Alternatively, several mutations can appear simultaneously in a few 
catastrophic genomic events.7 Malignant disease has traditionally been classified according to 
tissue type rather than mutational profile; however, new genome-wide DNA and RNA 
sequencing technologies have dramatically changed the understanding of the cancer 
genome.8,9 Tumors across different tissue types can show striking molecular similarities, 
while tumors of the same tissue type can display completely different mutational spectra, 
suggesting that the current tissue-specific classification might be inadequate.8 
The types of genetic events underlying cancer development have traditionally been classified 
into mutations, copy number alterations (CNAs) and rearrangements/translocations.5,10 In 
recent years, the term mutation, which refers to single nucleotide variants (SNVs) or small 
insertions/deletions (indels), has been widely replaced with the term sequence variant. In the 
context of cancer, sequence variants cause activation of oncogenes or inactivation of tumor 
suppressor genes. Similarly, CNAs result in amplifications of oncogenes or, more frequently, 
deletions of tumor suppressors. Through genomic rearrangements or translocations, parts of 
the genome are relocated, giving rise to fusions that alter the regulation of genes. The effect 
of these genetic lesions is executed at the protein level. In order to result in an oncogenic 
protein, an aberrant gene must first be transcribed into RNA molecules, which subsequently 
translate into the amino acid chain constituting the protein. Thus, studies of RNA expression 
generate insights into the functional effect of genomic aberrations.  
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1.1.1 Genetic analyses of cancer 
Traditionally, targeted methods, such as Sanger sequencing, fluorescent in situ hybridization 
(FISH) and real-time reverse transcriptase polymerase chain reaction (RT-PCR) have been 
used to detect the different kinds of genetic lesions or aberrant RNA expression.11 However, 
with the advent of massively parallel sequencing methods, all types of pathogenic lesions can 
be detected with the same method and in the same run.9,11 Whole genome sequencing (WGS) 
enables detection of mutations, small indels, CNAs and rearrangements present in both 
coding and non-coding genomic regions.12 With whole exome sequencing, the analysis is 
narrowed down to the 1,5 % of the genome that consists of coding genomic regions, i.e. the 
exons.13 Whole transcriptome sequencing (RNA sequencing) provides a simultaneous 
overview of gene expression levels, fusion gene transcripts and sequence variants in the 
transcribed DNA.14  
 
1.1.2 Prognostic genetic markers   
A prognostic factor is a patient characteristic that can be used to estimate the chance of 
recovery or the risk for relapse in a disease. In the field of cancer genetics, a prognostic 
marker refers to a genetic aberration in the tumor DNA that is associated with outcome. 
Traditionally, genetic cancer research has focused on driver mutations, i.e. highly oncogenic 
mutations providing strong growth capacities and usually present in a majority of cancer cells 
in diagnostic samples.5,6,15 The protein product of the mutated driver gene has been 
considered the most interesting target for new therapies. However, studies investigating 
paired diagnostic and relapse samples from the same patients have shown that this might be 
an oversimplification. A mutation considered as a driver in a diagnostic sample can be absent 
in the relapse sample, and conversely, the dominating clone in relapse samples can be absent 
at diagnosis or present in only a small fraction of cells in the diagnostic sample.16-18 
Furthermore, many solid tumors have been shown to harbor different clones in different parts 
of the tumor, a phenomenon termed tumor heterogeneity.19 A tissue sample will thus only 
show the mutational spectrum in a limited part of the tumor, possibly missing the clone with a 
relapse-prone mutation. Taken together, these factors represent challenges in the 
interpretation of both established and potential novel prognostic markers.  
 
1.2 LEUKEMIA 
In leukemia, pathological and dysfunctional blood cells accumulate and suppress the growth 
of functional red blood cells, platelets and immune cells, thereby causing the classical clinical 
symptoms fatigue, bleedings and infections, respectively.  
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1.2.1 Hematopoiesis and leukemia 
All blood cells originate from hematopoietic stem cells in the bone marrow. The 
hematopoietic stem cells have the ability to divide and differentiate through either the 
myeloid or lymphoid line in response to signals based on the current needs of the organism.20 
The myeloid line generates the red blood cells, responsible for oxygen transportation, the 
platelets, important for primary wound healing, and the granulocytes, which constitute the 
innate immune system. The lymphoid line gives rise to the adaptive immune cells, i.e. natural 
killer cells, B- and T-lymphocytes. In response to an infectious agent, the lymphoid stem cell 
differentiates into immature lymphoblasts, which eventually mature into lymphocytes, 
primed with customized proteins to target a particular infectious antigen.21 The 
transformation from hematopoietic stem cell to mature lymphocyte requires several steps of 
differentiation and maturation followed by rounds of proliferation, as well as genomic 
recombination.22,23 In B-cells, the recombination of immunoglobulin genes generates 
antibodies with affinity for a specific antigen. The different steps of proliferation and 
differentiation of lymphoblasts are largely regulated by the selective expression of 
hematopoietic transcription factors. Leukemia arises due to acquired mutations in 
hematopoietic stem cells or precursor cells, disrupting the tightly regulated growth-
differentiation-maturation process and resulting in pathological expansion of immature and 
dysfunctional cells.21,24  
In order to supply the body with enough blood cells, the bone marrow has a high baseline cell 
division rate, producing of over 1011 cells per day programmed to leave its primary tissue 
through the bloodstream. Furthermore, the cells of the adaptive immune system have a 
dynamic genome, inherently prone to genomic rearrangements.25 Thus, the normal, healthy 
immune cells display several cancer-promoting features:6 a high proliferation rate of 
immature cells, unstable genomes and the capacity to spread into the bloodstream.  
 
1.2.2 Classification of leukemia 
The term leukemia comprises several subtypes, with different but often overlapping clinical 
symptoms. Subtype classification is based on which hematopoietic line is affected, i.e. 
myeloid or lymphoid, as well as disease progression, i.e. acute or chronic. Morphologically, 
acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), are characterized 
by rapidly expanding immature progenitor cells, while their chronic equivalents show a 
gradual accumulation of more mature cells. The different leukemia subtypes are further 
characterized by different cytogenetic alterations that provide information on disease 
progress, prognosis and suitable treatment. In chronic myeloid leukemia (CML), all 
malignant cells harbor the t(9;22) translocation, i.e. the Philadelphia chromosome, which 
results in overexpression of the tyrosine kinase gene ABL1, and CML patients can be treated 
successfully with at tyrosine kinase inhibitor.26 In AML, mutations in the CREBBP, FLT3 or 
NPM1 genes provide important prognostic information.27 In chronic lymphocytic leukemia 
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(CLL), deletion of 11q2, including the ATM gene, and deletion of 17p13, are associated with 
poor survival.28 ALL has a high number of risk-associated genetic markers, with a total of six 
markers associated with adverse prognosis and relapse risk.29  
 
1.3 CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA 
While relatively uncommon in adults, ALL is the most frequent cancer type in childhood 
worldwide, accounting for approximately one third of all childhood cancers. In Sweden, the 
incidence is 3.6/100 000 children per year, with an incidence peak age of 2-5.30 Survival rates 
for childhood ALL have increased dramatically over the last four decades, mainly due to 
intensified treatment and refined risk stratification, but also improved supportive care.29,31,32 
 
1.3.1 Etiology 
A small fraction of childhood ALL cases have congenital genetic syndromes, such as Down 
syndrome (DS), Noonan syndrome or Fanconi anemia, that predisposes for leukemia 
development.33,34 Also, healthy carriers of a balanced Robertsonian translocation rob(15;21)c 
have a 2 700-fold increased risk of developing a specific subtype of ALL.35 However, the 
overwhelming majority of leukemia cases are caused by acquired mutations in the bone 
marrow cells and the etiology of leukemia in children without predisposing conditions is still 
largely unknown; the only proven risk factor for leukemia development is exposure to 
ionizing radiation.36 
The average childhood ALL case harbor few pathogenic mutations relative to adult cancers,8 
reflecting a time-dependent accumulation of mutations in adult cancers, but also that few 
mutations are needed to cause childhood ALL.  
Retrospective genetic analyses of Guthrie cards have shown that some of the leukemia-
associated translocations, including the t(12;21) ETV6/RUNX1 fusion, can be present already 
before birth in children who later develop leukemia, but also in children who do not develop 
this disease.37,38 This observation has generated the “two-hit” hypothesis of childhood 
leukemia, arguing that leukemia develops only after a second mutation occurs in a cell 
harboring a predisposing mutation (Figure 1). A few causes for susceptibly to a second hit 
have been suggested, including an aberrant immune response to infections early in life,39 or a 
low exposure to infectious agents during the first year, followed by over-response to common 
infections later in childhood,40,41 however, none of these hypotheses has been proven and 
different studies have shown conflicting results.     
Even though the majority of leukemia cases are caused by acquired mutations, familial 
clustering of childhood ALL cases does occur, suggesting that constitutional, predisposing 
factors exist. Recent research indicate that heritable predisposition is a much more important 
cause of childhood leukemia than previously thought. For example, inherited mutations in the 
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tumor suppressor gene TP53 are associated with increased risk for a particular high-risk 
leukemia subtype characterized by a hypodiploid karyotype.42 Recently, several other 
germline variants predisposing to childhood ALL have been reported.34 Genome wide 
association studies (GWAS) have shown association between increased risk of developing 
childhood leukemia and constitutional allele variants in genes involved in lymphocyte 
development and cell cycle regulation, including IKZF1, PAX5, CDKN2A/B, CEBPE, 
ARID5B and SH2B3 (Figure 1).43-46 GWAS have also revealed several inherited variants that 
affect the sensitivity to cytotoxic treatment, as well as risk variants for drug toxicities. Still, 
the knowledge of predisposing variants is too low to justify screening of healthy children in 
the current clinical setting.47  
 
 
 
 
Figure 1 – Schematic illustration of B-cell development and the timing of genetic alterations implicated in BCP 
ALL, including predisposing and leukemia-initiating lesions, followed by relapse-causing lesions that are either 
acquired during treatment or present in subclones at diagnosis; subclonality is represented by white and black 
cores in the ALL cells. Reprinted from Seminars in Hematology, Volume 50, Mullighan, Genomic 
characterization of childhood acute lymphoblastic leukemia, 314-324, 2013, with permission from Elsevier. 
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1.3.2 Diagnosis and treatment  
The first reported case of childhood leukemia was diagnosed and described by Dr. Henry 
Fuller in 1846.48 By that time, no treatment was available and children with leukemia did not 
survive the disease. In 1947, the pediatric oncologist Dr. Sidney Farber discovered that the 
drug aminopterin, a folic acid antagonist, induced temporary remission in children.49 The real 
treatment break-through came with the introduction of combinatory treatment, with different 
cytotoxic drugs used in different stages of the disease process.50  
1.3.2.1 Symptoms and diagnosis 
A child with leukemia presents with symptoms of a suppressed bone marrow, these include 
bone pain, fatigue, paleness, bruises, bleedings and infections. The diagnosis of ALL is 
verified by detection of a pathological number of immature B- or T-lymphoblast in the bone 
marrow. Analysis of the morphology and immunophenotype of the leukemic cells allows for 
subclassification according to the maturation stage of the leukemic blasts; about 80% of 
childhood cases have a precursor-B cell immunophenotype (BCP ALL).51  
1.3.2.2 Risk-assessment and treatment strategy 
The structure of the contemporary chemotherapy treatment strategy, including induction of 
remission, consolidation/intensification, and maintenance therapy, was established in the 
1980s.31 Several common treatment protocols have since been established around the world 
with the aim to unify diagnostics and treatment of childhood ALL. In Sweden, all children 
with ALL are diagnosed, risk-assessed and treated according to the common Nordic 
treatment protocol, Nordic Society of Pediatric Hematology and Oncology (NOPHO).32,52 
Induction treatment is started as soon as the bone marrow examination has verified the 
diagnosis, and the preliminary risk-assessment is based on clinical risk factors, including 
white blood cell (WBC) count, age and the presence of extra-medullary disease.32 Response 
to treatment is monitored by minimal residual disease (MRD), i.e. amount of remaining 
leukemic blast in bone marrow samples taken at specific time points.32,53 MRD is currently 
considered one of the most powerful indicators for outcome in childhood ALL.54-56 Also, 
cytogenetic analyses provide crucial information about prognosis and risk for relapse.29 At 
day 29 of treatment, the risk profile is re-assessed based on results from cytogenetic analysis 
and MRD, and the treatment intensity is adjusted accordingly.53 As a result of this risk-
adapted treatment strategy, as well as improved supportive care, overall survival rates exceed 
80% in modern protocols.31,32 However, 10–20% of patients relapse, and the survival rate for 
relapsed ALL is poor.57 
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1.3.3 Risk-associated cytogenetic markers in childhood ALL 
The presence of acquired genetic aberrations in the leukemic blasts constitutes the basis for 
risk stratification and guides treatment intensity.29,32,58-60 Targeted genetic analyses of the 
diagnostic bone marrow sample are performed based on the pathology findings. The current 
standard genetic work-up for ALL includes G-banding for detection of aneuploidies, and 
FISH or RT-PCR analysis for detection of translocations. The frequencies of cytogenetic 
markers detected in childhood ALL at diagnosis are depicted Figure 2.  
 
 
 
Figure 2 – Pie chart showing distribution of risk-stratifying genetic markers in childhood BCP ALL at 
diagnosis; B-other represents cases without any of the currently used markers  
 
1.3.3.1 Standard-risk genetic markers  
High hyperdiploidy (HeH) and t(12;21) translocation are the most common cytogenetic 
subtypes in childhood ALL, present in 25% of cases respectively. The HeH subtype is 
defined as 50-67 chromosomes; the gained chromosomes are typically chromosome X, 4, 6, 
10, 14, 17, 18 and 21, but why these chromosomal gains give rise to leukemia is not known.61 
The t(12;21) translocation causes the ETV6/RUNX1 fusion; both ETV6 and RUNX1 are 
hematopoietic transcription factors, but the disease causing mechanism is not known. As 
mentioned above, this fusion can be present in bone marrow cells already in utero,37,38 and 
additional genetic lesions are needed to cause overt leukemia. Additional leukemia-associated 
genetic alterations are present in a majority of HeH and t(12;21) cases.62,63 Both these 
subtypes are associated with favorable clinical parameters and outcome, however if other 
clinical or molecular signs of higher risk are present, the patient will be stratified according to 
these. 
Hypodiploidy,)2%) KMT2A,
rearragement,)6%)
t(1;19),)5%)
iAMP21,)2%)
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1.3.3.2 Intermediate-risk genetic markers 
The t(1;19) translocation, the dicentric (9;20), and intrachromosomal amplification of 
chromosome 21 (iAMP21) are the three markers associated with intermediate risk in 
NOPHO. The t(1;19) translocation, present in 5-6% of childhood ALL, causes the 
TCF3/PBX1 fusion and gives rise to an aberrant protein with oncogenic properties.64 The 
dicentric (9;20)(p13;q11) subtype is present in 5% of childhood cases in the Nordic countries 
and associated with poor prognosis if treated according to standard risk protocols.65 The 
aberration is characterized by additional genetic alterations, i.e. homozygous loss of 
CDKN2A and heterozygous loss of PAX5,66 but the mechanism behind the higher risk profile 
is not fully understood. IAMP21 is present in 2% of pediatric BCP ALL cases and is 
associated with high age at diagnosis (median age 9) and low WBC.67,68 IAMP21 is 
considered a primary event, with the amplification present in all subclones and always 
retained at relapse.69 Although studies have described the genetic composition and the likely 
mechanisms of formation in iAMP21,35,69-72 the mechanism underlying the higher relapse risk 
of this subtype is not understood. Recurrent alterations, such as deletion of ETV6, IKZF1 and 
RB1, as well as P2RY8/CRLF2 translocations have been reported.69,73 However, the only 
genetic alteration consistently present in all iAMP21 cases is additional copies of the region 
of amplification.69 The minimal region of amplification encompasses several protein coding 
genes, including RUNX1, but to this date, no causative gene has been identified in the region.  
Retrospective studies have demonstrated that both the iAMP21 and t(1;19) subtype are 
associated with a high relapse rate if treated according to standard-risk protocols,60,74,75 but 
the prognosis improves when they are treated according to intermediate or high-risk 
protocols. 
1.3.3.3 High-risk genetic markers  
Three cytogenetic markers are currently associated with high risk of relapse or treatment 
failure, these are hypodiploidy, rearrangements of the KMT2A gene at 11q23 (previously 
known as MLL) and the t(9;22) translocation (Philadelphia chromosome). The hypodiploid 
subtype is further subclassified into hypodiploid (44 chromosomes), high hypodiploid (40 to 
43 chromosomes), low hypodiploid (33 to 39 chromosomes) and near-haploid (23 to 29 
chromosomes). The two latter are associated with a very poor outcome while the high 
hypodiploid group is more heterogenous with varying outcome.76,77 Studies have shown that 
both the near-haploid and low hypodiploid subtype harbor recurrent activating mutations in 
kinase genes, some sensitive to PI3K/mTOR inhibitors,42 suggesting a role for kinase 
inhibitors in the treatments of these patients. Moreover, studies have shown that near-haploid 
cases often have a fraction of cells with duplication of the haploid clone, masking as 
hyperdiploid clones.78 Methods that detect uniparental disomies (UPDs) are needed to 
identify these, in order to prevent misclassification.  
Rearrangements of KMT2A are present in approximately 80% of infant ALL cases and affect 
a total of 5-6% of childhood ALL cases.79 KMT2A encodes a transcriptional regulator that 
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affects the expression of several important hematopoietic development genes. Over 80 
different genes have been reported to form fusions with, and affect the activity of, the KMT2A 
gene in this rearrangement, and the most common partners are AFF1 (4q21) and MLLT1 
(19p13.3).80  
The t(9;22) translocation, which causes the BCR/ABL1 fusion and subsequent over-activity of 
the ABL1 tyrosine kinase, is one of the best-understood genetic subtypes in leukemia. While 
the translocation is associated with favorable prognosis and long-term survival when treated 
with kinase inhibitors in CML,26 the prognosis for BCR/ABL1-positive ALL and CML in 
blast crisis is poor.81 The BCR/ABL1 fusion is present in 3% of childhood ALL, and these 
patients receive additional treatment with a tyrosine kinase inhibitor according to a special 
protocol.32   
1.3.3.4 Challenges in genetic diagnosis of ALL 
Several issues remain to be solved in the clinical genetic diagnostics of childhood ALL. First, 
approximately 25% of cases harbor none of the currently used genetic risk markers; these are 
referred to as B-other and constitute a substantial proportion of cases that subsequently 
relapse.82 B-other is a heterogeneous group with either seemingly normal or failed karyotypes 
or aberrations of unknown or undetermined significance in their leukemic cells. For these 
cases, routine genetic work-up fails to contribute to the risk assessment. Second, genetic 
markers associated with high risk are infrequent and do not correspond to all cases that 
relapse or fail treatment. Third, relapses occur across all genetic subtypes, including those 
associated with a favorable outcome, such as HeH and t(12;21). Fourth, the molecular 
mechanisms responsible for relapse risk or treatment failure in the intermediate/high-risk 
subtypes remain largely unknown. Taken together, these issues indicate that additional or 
more adequate prognostic markers are needed. 
 
1.3.4 Emerging subtypes in ALL 
During the last decade, the development of large-scale methods for analysis of the genome and 
the global gene expression pattern in malignant cells have provided insights to the molecular 
landscape of childhood ALL. Novel prognostic markers have been proposed, however the 
prognostic impact of these markers could not always be confirmed in other patient cohorts. 
This discrepancy is likely explained by differences in risk profiles of the different cohorts, but 
also by differences in treatment intensity and possibly even variation in the germline genetic 
background of patient cohorts. This implies that potential markers have to be tested and 
verified within the respective treatment protocols before they can be implemented in routine 
diagnostics.  
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1.3.4.1 The copy number landscape of ALL 
In 2007, the first genome-wide copy number studies of ALL, using array-based comparative 
genomic hybridization (array-CGH) or single nucleotide polymorphism (SNP) arrays, could 
demonstrate that copy number alterations (CNAs) are frequent in ALL.83-85 Since then, 
numerous studies have shown that CNAs play an important role in leukemia development and 
several potential prognostic markers have been proposed, mainly deletions in genes involved in 
lymphoid development, cell cycle regulation and apoptosis.17,71,86-89 Deletions of the lymphoid 
transcription factor genes IKZF1 and VPREB1 have been associated to poor prognosis,88-90 
while deletions of the transcriptional regulator gene ERG have been suggested to correlate with 
favorable outcome in cases with IKZF1 deletions.91,92 Deletions of CREBBP, TBL1XR1 and 
SPRED1 have been detected in a high proportion of paired diagnostic and relapse samples;93-96 
this may suggest a relapse-prone effect of these aberrations. Interestingly, CREBBP deletions 
are present in relapsed HeH cases, indicating that this deletion might counteract the otherwise 
favorable prognosis for this subtype.97 Similarly, deletions of the lymphoid development gene 
VPREB1 have been associated to relapse and poor prognosis in cases with the standard-risk 
marker t(12;21).90 Deletions of these genes have also been reported in a newly described type 
of leukemia, i.e. “early-T-cell”, a subtype characterized by poor prognosis and deletions of 
tumor suppressors, activating mutations in oncogenes and inactivating mutations in epigenetic 
regulators.42 
1.3.4.2 The Philadelphia-like subtype 
In 2009, two independent research groups reported on a novel high-risk subtype of B-ALL, 
with a gene expression profile similar to BCR/ABL1-positive ALL but lacking the canonical 
fusion gene.88,98 This subtype, termed “Philadelphia-like ALL”, harbored aberrations in 
tyrosine kinase genes, as well as recurrent deletions of the transcription factor IKZF1. 
Patients with this profile in the leukemic cells had a poor outcome, with high MRD levels at 
the end of induction and resistance to the cytotoxic drugs asparaginase and daunorubicin. The 
profile was present in ~10% of childhood ALL cases and a majority of these harbored no 
known risk-stratifying genetic markers, pointing to a prognostic relevance of this subtype. 
However, the clinical relevance of this subtype has been debated; while several studies have 
observed a poor prognosis for this subtype,99,100 others have indicated that MRD-based risk-
stratification is sufficient to counteract this negative prognostic effect.101 Further studies have 
shown that activating mutations in kinase genes, including ABL1, CRLF2, PDGFRB and 
JAK2, are present in over 90% of the cases,102,103 and many of these are targetable for kinase 
inhibitors. These novel insights in the aberrant kinase signaling in ALL suggest that a 
substantial proportion of ALL cases could potentially be treated with tyrosine kinase 
inhibitors. 
1.3.4.3 Overexpression of CRLF2  
Overexpression of the JAK-STAT kinase gene CRLF2 is present in approximately 6% of 
childhood BCP ALL cases, and 50% of these harbor additional high-risk aberrations such as 
JAK-mutations or IKZF1 deletions.104 Overexpression of CRLF2 can be caused either by 
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deletion of the pseudoautosomal region 1 (PAR1) at Xp22/Yp22, which juxtaposes the 
P2RY8 gene to CRLF2, or by illegitimate recombination between the immunoglobulin gene 
IGH and the CRLF2 gene; in both instances, the new partner gene causes an overexpression 
of CRLF2. In rare cases, overexpression is caused by gain-of–function mutations in CRLF2. 
However, while this subtype was associated with inferior outcome in the first studies that 
described the alteration,105 this correlation has not always been reproducible in other 
cohorts.100  
1.3.4.4 DUX4-rearranged and ETV6/RUNX1-like ALL 
A recent study of the fusion gene landscape of BCP ALL showed that 4% (8/195) of the total 
cohort, and 16% (8/50) of B-other cases, harbored fusion rearrangements involving the DUX4 
gene, i.e. DUX4/IGH or DUX4/ERG.106 All rearrangements caused overexpression of DUX4 
and aberrant expression of ERG. DUX4 encodes a transcription factor that regulates the 
expression of stem-cell development genes, which suggests that its overexpression might 
cause activation of stem cell programs.106 Other studies have supported the finding of a 
DUX4-rearranged subtype,107,108 and the DUX4 rearrangement has been proposed as an early, 
leukemia-initiating event, where binding of DUX4 to the ERG gene causes deregulated 
expression of coding and noncoding ERG transcripts. DUX4/ERG ALL has been associated 
with ERG deletions and favorable outcome, irrespective of co-occurring negative prognostic 
genetic alterations such as IKZF1 deletion.108 
Another finding in the first study106 was a novel subtype with an ETV6/RUNX1-like 
expression profile but lacking the canonical fusion, present in 12% of B-other cases; all cases 
harbored aberrations in ETV6 and IKZF1, and the subtype was associated with favorable 
outcome despite the presence of IKZF1 deletions.106 
 
1.3.5 IKZF1 deletions in childhood ALL 
Deletion of the IKZF1 gene (∆IKZF1), encoding the transcription factor IKAROS, occurs in 
approximately 15% of pediatric BCP ALL.88,89,95,109,110 ∆IKZF1 was originally described in 
association with the high-risk subtype BCR/ABL1-positive ALL, and was thought to 
contribute to the poor prognosis of this subtype.111 In 2008, a large study on copy number 
alterations in ALL could demonstrate that ∆IKZF1 was significantly associated with relapse 
in BCR/ABL1-negative BCP ALL,17 suggesting a negative prognostic impact in all types of 
BCP ALL.  
1.3.5.1 Functional effect of IKZF1 deletions  
The IKZF1 gene is located on chromosome 7q11, and the majority of reported aberrations in 
this locus are deletions; sequencing of IKZF1 has shown a low frequency of point 
mutations.89,100,111,112 Heterozygous deletions of the entire IKZF1 locus or individual exons 
are predicted to cause haploinsufficiency, whereas deletion of a specific subset of exons (4-7) 
result in expression of IK6, a shorter, dominant-negative isoform of IKAROS.81,111,113  
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In normal B-cell development, different isoforms of IKZF1, generated through alternative 
splicing, are expressed during different development stages.114 However, the IK6 isoform is 
considered a pathogenic isoform caused by deletion only.115 The most frequently occurring 
intragenic ∆IKZF1 in childhood BCP ALL are shown in Figure 3.  
While some studies have suggested that haploinsufficiency of IKAROS contributes to 
leukemia development through disruption of maturation signaling, with subsequent 
uncontrolled growth of immature B-cells,116 others have indicated that ∆IKZF1 might occur 
only as a symptom of a general genomic instability, and that the genetic instability is the true 
cause of relapse and treatment failure.117 The latter theory is contradicted by the results from 
a recent SNP-array study, in which no significant difference in the frequencies of CNAs 
between ∆IKZF1-positive and ∆IKZF1-negative cases was detected.95 
 
 
Figure 3 – Schematic illustration of the IKZF1 gene; red bars represent the exonic regions most commonly 
affected by intragenic deletions in childhood BCP ALL 
 
1.3.5.2 IKZF1 deletion as a prognostic marker 
Since the study in 2008, several research groups have verified a significant association 
between ∆IKZF1 and reduced event-free survival (EFS) and overall survival (OS) in 
ALL.88,89,95,100,109,110,112 Of particular interest is the observation that ∆IKZF1 confers a poor 
prognosis in cases without established risk-stratifying aberrations.88,89,100 Moreover, ∆IKZF1 
is frequently occurring in the Philadelphia-like subtype mentioned in the previous section.88,98 
However, studies have also suggested that the prognostic impact of ∆IKZF1 might be 
modified by other co-occurring genetic aberrations, such as deletions of the ERG gene and 
rearrangements of the CRLF2 gene, or by treatment intensity, as well as by MRD 
stratification.91,92,118-120 Thus, different studies have been conflicting as to whether ∆IKZF1 
represents an independent risk factor or not.100,109,112,118,120 Despite numerous studies, there is 
no consensus regarding the relevance in using ∆IKZF1 as a prognostic marker in the routine 
diagnostic setting.  
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2 AIM OF THESIS 
The overall purpose of this thesis was to characterize genetic alterations underlying leukemia 
in children, with the primary aim to identify novel recurrent genetic lesions and evaluate their 
relevance for disease progression and outcome in pediatric ALL. These novel genetic 
markers might complement or replace current prognostic markers and facilitate clinical 
decision-making. A secondary aim was to evaluate alternative genetic analysis methods to 
detect novel as well as established markers in the routine laboratory diagnostics.  
 
Specifically, the aims of thesis were to: 
 
• Determine the frequency and prognostic impact of IKZF1 deletions in childhood ALL 
treated according to NOPHO protocols 
 
• Characterize and compare copy number profiles across cytogenetic subtypes of 
childhood ALL and identify focal alterations associated with leukemia development  
 
• Investigate the genomic structure and transcriptional effects of the iAMP21 alteration 
in childhood ALL using massively parallel sequencing and genome-wide arrays 
 
• Improve the sensitivity and efficiency of the genetic diagnostics of ALL 
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3 MATERIAL AND METHODS 
3.1 PATIENTS AND CLINICAL DATA  
All samples used in the studies were retrospectively collected from biobanks; residual bone 
marrow samples from children diagnosed with ALL from 1995 and onwards have been 
routinely saved at the Karolinska University Hospital as well as in a common NOPHO 
biobank. Clinical data for all cases, including clinical parameters, molecular findings and 
survival data, were extracted from the NOPHO database. 
 
3.1.1 Patient cohort paper I and II 
In paper I, DNA from a consecutive cohort of children (age 1–18) diagnosed with BCP ALL 
between 2001 and 2011 at the Karolinska University Hospital in Stockholm was used. During 
these years, a total of 148 children were diagnosed with BCP ALL in Stockholm; DNA from 
diagnostic bone marrow aspirates was available from 120 of those cases. Infant ALL cases 
were excluded. Among the 120 cases included in the study, 86 were treated according to the 
NOPHO-2000 protocol and the remaining 34 were treated according to the current NOPHO-
2008 protocol. Median age was 5 years, with a male to female ratio of 1:1 and a median 
diagnostic WBC count of 9.5 x 109/l. Risk group assignment within the NOPHO protocol had 
classified 40% of the cohort as standard-risk (SR; n=48), 44% as intermediate-risk (IR; n=53) 
and 16% as high-risk (HR; n=19) ALL. A majority of cases (72/120) harbored low-risk 
cytogenetic markers, i.e. HeH and t(12;21), a few (13/120) had intermediate risk markers, i.e. 
iAMP21, t(1;19) or dic(9;20), and one patient was diagnosed with a high-risk, hypodiploid 
leukemia. In total, 34 out of 120 patients (28%) showed no risk-stratifying genetic markers at 
diagnosis. Two of these had Down syndrome ALL (DS-ALL). Only two BCR/ABL1-positive 
ALL cases were diagnosed in Stockholm during this time period and no DNA was available 
from these patients.  
Paper II included all BCP ALL cases diagnosed in Sweden between 1992 and 2013 that had 
available IKZF1 gene dose data (n=354). Thirteen of the 354 cases were infant ALL and 
seven were BCR/ABL1-positive; these 20 cases were excluded from further analysis. Among 
the remaining 334 cases, 23% (76/334) were treated according to NOPHO-1992, 43% 
(143/334) according to NOPHO-2000 and 34% (115/334) according to NOPHO-2008. Risk 
stratification at diagnosis had divided the patient into standard-risk (SR; n=136), 
intermediate-risk (IR, n=140) and (HR; n=58). The median age was 4 years (range 1–17 
years), the male to female ratio 1:1 and the WBC count 9.7 x 109/l (range 0.9–1161 x 109/l). 
The cohort comprised 95 (28%) B-other cases, the remaining 239 (72%) cases harbored 
stratifying cytogenetic markers.  
In the years between 1992 and 2013, a total of 1 133 Swedish children (1–17 years) were 
diagnosed with BCR/ABL1-negative BCP ALL and treated according to NOPHO protocols. 
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A comparison of the 334 (29%) cases used in this study with the 799 (71%) cases with 
unknown IKZF1 status did not show significant differences with regard to clinical/molecular 
parameters or survival frequencies; the only exception was the median WBC count, which 
was significantly higher in the investigated cohort.  
 
3.1.2 Patient cohort paper III 
In paper III, 50 childhood BCP ALL cases diagnosed between 2001 and 2013 at the 
Karolinska University Hospital were included. Cases diagnosed between 2001 and 2008 
(n=23) were selected to include common cytogenetic subtypes but also to maximize for cases 
without known risk-associated genetic aberrations, i.e. “B-other”. Cases diagnosed 2009 and 
onwards (n=27) were consecutive. Thirty of the 50 cases had known cytogenetic markers, i.e. 
HeH (n=12), t(12;21) (n=9), t(1;19) (n=3), iAMP21 (n=3), t(9;22) (n=2), and KMT2A  
rearrangement (n=1). The remaining 20 cases were classified as B-other. All patients were 
treated according to NOPHO protocols except for one infant ALL and two t(9;22)-positive 
ALL cases. Median age at diagnosis was 5.5 years (range 0–18 years) and the median WBC 
count was 20.1 x 109/l (range 1.2–775 x 109/l). Two patients had DS-ALL. MRD values from 
end of induction (day 29) were available for 37 of the 50 cases; a majority of these cases had 
a positive MRD value (23/37).  
The study also included a validation cohort, comprising 191 consecutive pediatric cases 
diagnosed with BCP ALL at the Departments of Pediatric Oncology and Hematology, Lund 
and Linköping University Hospitals, Sweden. A majority of these harbored known 
cytogenetic risk-markers, i.e. HeH (n=56), t(12;21) (n=40), t(1;19) (n=8), iAMP21 (n=2), 
t(9;22) (n=5), KMT2A rearrangements (n=9), hypodiploidy (n=4), while 35% (n=67) 
corresponded to B-other or failed karyotypes.  
 
3.1.3 Patient cohort paper IV 
For paper IV, 16 cases diagnosed with iAMP21-positive BCP ALL between 1992 and 2014 
were selected; one case did not have sufficient material available and the remaining 15 were 
included together with relapse samples from two of the patients. The cohort represented all 
known iAMP21-positive ALL cases available (n=12), with the addition of three cases for 
which the iAMP21 was identified retrospectively through a BCP ALL methylation classifier 
described in a study by Nordlund et al.121 Patients were treated according to the NOPHO 
ALL-1992 (n=2), ALL-2000 (n=11) and ALL-2008 (n=2) protocols. The median age at 
diagnosis was 9 years (range 5-17 years) and the median WBC count was 5.5 x 109/l (range 
1.7 - 61.5 x 109/l). An additional cohort of 34 BCP ALL cases without iAMP21, i.e. dic(9;20) 
(n=14), HeH (n=6), 11q23 translocation (n=4), t(12;21) (n=4), t(9;20) (n=4) and B-other 
(n=2), was included to study differential gene expression. 
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3.2 MOLECULAR ANALYSES 
 
3.2.1 Diagnostic cytogenetic analyses  
At the time of diagnosis, the bone marrow samples of patients had been analyzed using 
chromosome banding and FISH to detect aneuploidies/gross rearrangements and risk-
associated structural abnormalities respectively. FISH analysis with commercial probes had 
been used to screen for the t(1;19)(q23;p13) TCF3/PBX1, t(9;22)(q34;q11) BCR/ABL1, 
t(12;21)(p13;q22) ETV6/RUNX1 and KMT2A (MLL) rearrangements, as well as iAMP21; 
iAMP21 was defined as >5 signals from the RUNX1 probe, given that polysomy 21 had been 
excluded. The FISH probes used for detection of dic(9;20) had been designed and evaluated 
in paper VI before implemented in the routine diagnostics of ALL. All cytogenetic findings 
had been centrally reviewed by the NOPHO cytogenetic group. 
3.2.1.1 DNA and RNA extraction 
The DNA used for papers I and III had been extracted from bone marrow aspirates at the 
time of diagnosis using the Gentra Puregene Tissue kit (QIAgen, Hilden, Germany) for cases 
diagnosed prior to 2009, and the QIAgen AllPrep (QIAgen) for cases from 2009 and 
onwards. For paper IV, DNA and RNA from diagnostic bone marrow samples were 
extracted for the purpose of the study, using the QIAgen All-Prep DNA/RNAMini kit. RNA 
sample quality was measured using the RNA Nano Assay 6000 on a Bioanalyzer 2100 
(Agilent Technologies, Santa Clara, CA, USA); only RNA samples with a RNA integrity 
number (RIN) above 7 were used in study IV.  
 
3.2.2 Targeted copy number analysis: MLPA  
In paper I, multiplex ligation-dependent probe amplification (MLPA) was used to detect 
IKZF1 deletions in 120 consecutive childhood ALL cases. MLPA is a multiplex variant of 
polymerase chain reaction (PCR), which allows for multiple genetic sites to be tested in the 
same run. Two oligonucleotide probes are designed for each target site; when both probes 
bind correctly, they are ligated to a complete probe, which is subsequently amplified by PCR. 
Each ligated probe has a unique length discernable by electrophoresis, and the forward primer 
is labeled with fluorescent dye, making it detectable on a capillary sequencer. The relative 
quantity of each amplified probe, i.e. the peak height, is normalized against control samples 
to generate relative copy number (CN) states of the target site in the sample. In our study, we 
used the commercial probe kits P335 and P202 (MRC-Holland, Amsterdam, The 
Netherlands). The P335 probe mix contains one probe per coding exon of the IKZF1 gene, as 
well as probes for exons in the PAX5, ETV6, RB1, BTG1, EBF1, CDKN2A/B and PAR1 
(SHOX, CRLF2, CSF2RA, IL3RA, and P2RY8) genes. Relative peak heights between 0.75 
and 1.35 were considered normal (CN=2); values below 0.75 and above 1.35 were considered 
as deletions (CN ≤1) or duplications/amplifications (CN ≥3) respectively. Values below 0.25 
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indicated biallelic loss (CN=0). Four samples failed MLPA due to poor sample quality. 
Samples with deletions in IKZF1 were further analyzed with the probe kit P202, which 
contains two probes per exon of IKZF1.  
 
3.2.3 Genome wide copy number analyses: array-CGH and SNP-array 
In paper II-IV, genome-wide array methods were used to detect copy number alterations 
(CNAs). In paper III, we used array comparative genomic hybridization (array-CGH) to 
investigate the study cohort (n=50). With this method, patient reference DNA are labeled 
with two different fluorescent dies respectively and hybridized to probes attached to a glass 
slide or a filter; the signal intensities of patient and reference DNA are compared and 
translated into a log2 ratio in order to detect copy number imbalances in the patient DNA. 
The resolution of array-CGH is determined by the size of the probes and the genomic 
distance between the probes. In our study, samples diagnosed between 2001 and 2008 (n=23) 
and samples from 2009 and onwards (n=27) were run on slightly different 4 x 180K array-
CGH platforms from OGT (Oxford Gene Technology, Oxfordshire, UK), however average 
probe spacing for both platforms was 20 kb and the resolutions were comparable. To allow 
detection of subclonal CNAs, a cutoff log2 ratio corresponding to heterozygous loss or gain 
in >50 % of input DNA was set. Focal CNAs were defined as CNAs spanning less than 0.3 
Mb and including only one or few genes. All data analyses were performed using the 
CytoSure Interpret software (OGT). 
In papers II, III and IV, single nucleotide polymorphism (SNP) arrays were used. Similar to 
array-CGH, sample probe intensities are normalized against reference samples to produce 
log2 ratios centered at zero for a diploid sample, and log2 ratios are grouped using circular 
binary segmentation. However, in addition to CNAs, the SNP-array can detect SNPs and loss 
of heterozygosity (LOH). Of the 334 cases in paper II, 218 (65%) had been analyzed by 
SNP arrays at the respective center, using Human-OmniExpress BeadChip (Illumina, San 
Diego, CA, USA), Human 610-Quad BeadChip (Illumina), HumanOmni1-Quad BeadChip 
(Illumina), Human1M-Duo BeadChip (Illumina) or Genome-Wide Human SNP Array 6.0 
(Affymetrix, Santa Clara, CA, USA). The CN state was determined using the GenomeStudio 
2011.1 (Illumina), Chromosome Analysis Suite (Affymetrix), or the Nexus Copy Number 
(BioDiscovery, Hawthorne, CA, USA) software. Deletions affecting segments of ≥3 
consecutive probes were included in the study. The remaining 116 cases (35%) included in 
paper II represented the cohort analyzed with MLPA in paper I; a comparison between 
cases identified by SNP arrays (n=218) and MLPA (n=116) showed no significant 
differences regarding clinical features or deletion types. 
The validation cohort in paper III had been analyzed using the HumanOmni1-Quid and 
Human1MDuo array systems (Illumina) and CNAs were calculated using The Genome 
Studio Software 2011.1 (Illumina). In paper IV, the cohort was analyzed with SNP array 
platforms Omni 2.5M (n=9) or Omni 2.5M+Exome (n=4) (Illumina Inc, San Diego, CA, 
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USA), containing 2.5 million probes each. Segments of ≥10 consecutive probes and spanning 
≥20 kb were included in the analysis. Annotation and filtering was performed using BEDOPS 
v2.4.2122 R v3.1.0 and processed data was visualized using the Integrative Genomics Viewer 
(IGV) v2.3.42.123  
In all these papers, CNAs previously reported as benign copy number variants in the 
Database of Genomic Variants (http://dgv.tcag.ca/dgv/app/home) and/or in local in-house 
hospital databases were generally excluded from further analysis. 
 
3.2.4 Whole genome sequencing 
In paper IV, DNA from diagnostic iAMP21-positive ALL cases (n=3) was analyzed with 
mate-pair whole genome sequencing (MP-WGS). The mate-pair technique generates long 
reads, suitable for structural variant detection. In mate pair library preparation, an initial 
fragmentation generates relatively long DNA fragments; these are end-labeled and 
circularized before subsequent fragmentation and paired-end sequencing. The sequenced 
short reads correspond to the ends of a longer DNA fragment, and thus the structure of the 
longer DNA sequence can be deduced from the genomic positions of the end sequences. This 
method was also used in paper VIII, with the purpose to evaluate the method for the routine 
diagnostics of ALL. In both paper IV and VIII, mate-pair libraries were prepared from 
diagnostic DNA using Illumina's Nextera Mate Pair Sample Preparation Kit, according to 
manufacturers instruction for a gel-free preparation of 2 kb effective insert size library. The 
libraries were sequenced on an Illumina HiSeq 2500 sequencer, 2x100 bp to an average raw 
coverage depth of ~5x. Adapter sequences were removed using Trimmomatic v0.32 and 
remaining pairs were aligned to the hg19 GRCh37 human reference genome sequence using 
bwa-mem version 0.7.4124 resulting in a 3X mapped coverage. Mapped reads were analyzed 
for intra- and interchromosomal rearrangements using FindTranslocations 
(https://github.com/vezzi/Find Translocations), a locally developed software implementing a 
sliding windows analogue of a previously published procedure.125 All rearrangements and 
translocations were manually inspected in IGV version 2.42.18.123 
 
3.2.5 DNA methylation analysis 
In paper IV, previously published data on DNA methylation levels from eight diagnostic 
iAMP21 samples were reanalyzed. In the previous study, the iAMP21 cases had been 
included as part of a training set to build subtype-specific DNA methylation classifiers, which 
were further tested in paper VIII. In paper IV, the iAMP21 samples (n=8) were compared 
to diagnostic BCP ALL samples without iAMP21 (n=665) and to 25 CD19+ B-cells from 
healthy blood donors using the non-parametric Wilcoxon rank-sum test to investigate 
differential methylation in iAMP21. The mean, standard deviation (SD), and 
mean methylation difference between the two groups was measured. Minimal cut-off value 
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for the mean absolute differences in DNA methylation (∆β) was set to ≥20% in order to 
identify CpG sites with large difference between the groups. The p-values were corrected for 
False Discovery Rate (FDR) due to multiple testing. 
 
3.2.6 RNA sequencing 
In paper IV, RNA from diagnostic (n=12) and relapse (n=3) iAMP21-positive ALL samples 
was analyzed using whole transcriptome sequencing (RNA sequencing). Samples were first 
treated with RiboZero (Epicentre, Madison, WI, USA) in order to eliminate ribosomal RNA. 
Next, strand-specific RNA sequencing libraries were prepared using ScriptSeq v2 
(Epibio.com) and sequenced 50 bp paired-end on Illumina HiSeq 2000/2500, producing ~100 
million read pairs per sample. Sequence reads were aligned to the human genome reference 
build GRCh38 (hg38) using Spliced Transcripts Alignment to Reference (STAR) version 
2.4.0j126 with exon junction support from Ensembl gene annotation version 77. The trimmed 
mean of M-values normalization method127 was used for normalization of raw read counts, 
and Voom128 was used for variance normalization. Genes with a count of ≥ 1 per million 
mapped reads (CPM), in ≥ 2 samples, were included for further analysis. Gene expression 
levels were also normalized to reads per kilobase per million mapped reads (RPKM). Raw 
sequence reads in fastq format were further analyzed for the presence of fusion genes using 
FusionCatcher.  
3.2.6.1 Differential gene expression 
Analysis of differential gene expression was performed using the R/Bioconductor package 
limma.129 Twelve iAMP21-positive cases were contrasted against the combined average 
expression of a total of 46 BCP ALL cases. Unsupervised hierarchical clustering was 
performed using Eucledian distances and complete linkage and significance tested by F test 
statistic in Limma.  
3.2.6.2 Sequence variant analysis 
The cDNA sequencing reads were aligned to the human genome reference GRCh37 (hg19) 
and nucleotide variants were detected by using STAR126 with exon junction support from 
Ensembl gene annotation version 75. Sequence reads that overlapped exon junctions were 
split and trimmed to exon boundaries using GATK version 3.2-2.130 Duplicate reads, 
clustered SNPs (≥3 within 35bp), variants with high Fisher strand values (FS>30) or low 
depth-adjusted quality scores (QD<2), were excluded from further analysis. No constitutional 
DNA was available for filtering. Variants were annotated and assessed using Ensembl 
Variant Effect Predictor131 and GEMINI132, with the following criteria for putative somatic 
variants in the minimal region of amplification on chromosome region 21q: 1) non-
synonymous variant; 2) in a coding region; 3) supported by ≥ 10 variant reads, with a 
minimum of 20 total reads; 4) not in a repeat masked region. Variants outside of the MRA 
were additionally filtered on potential pathogenicity using Scaled Combined Annotation 
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Dependent Depletion (CADD),133 with a cut-off score of ≥15. Filtered variants were further 
tested against previously registered cancer relevant variants in the COSMIC 
(http://cancer.sanger.ac.uk/cosmic/) and the Pediatric Cancer Genome Project 
(https://pecan.stjude.org/) databases.  
 
3.3 VALIDATIONS 
In paper I, all detected deletions affecting the IKZF1 gene were validated with the P202 kit; 
deletions that affected single IKZF1 exons with the P335 kit were only included if validated 
by the P202 kit. In paper III, all CNAs were manually inspected using CytoSure (OGT) and 
IGV134, and a consecutive cohort of 191 cases analyzed by SNP-array was used for validation 
of novel CNAs. Validated CNAs were less frequent in the validation cohort, likely due to a 
higher proportion of B-other cases as well as to the inclusion of subclonal CNAs in the study 
cohort. In paper IV, the rearrangement breakpoints in chromosome 21 detected by MP-WGS 
were manually inspected at the nucleotide level using IGV, and validated using PCR for 
sample KSALL11. The PCR primers were designed using Primer3Plus.135 Recurrent fusion 
transcripts were validated using RT-PCR and Sanger sequencing of the cDNA fusion 
breakpoint.  
 
3.4 STATISTICAL ANALYSES  
All clinical data were retrieved from the NOPHO database. In papers I and III, statistical 
calculations were performed using the SPSS software (SPSS Inc., Chicago, IL, USA). The 
significance limit for two-sided p-values was set to <0.05. In papers I and II, the Kaplan-
Meier method was used to calculate the probabilities of event-free survival (pEFS) and 
overall survival (pOS) at 10 years after diagnosis; groups were compared using the log rank 
test. The events in the pEFS analysis were defined as induction failure, relapse, death in first 
remission and second malignant neoplasm. In the analysis of pOS, death was the only end 
point. To assess the independent impact of IKZF1 deletion on survival, multivariate analyses 
adjusting for common risk factors were performed using the Cox proportional hazard 
regression analysis.  
In paper II, clinical and genetic features between cases with known IKZF1 status (n=334) 
and those with unknown IKZF1 status (n=799) as well as between IKZF1 deleted (n=50) and 
non-deleted cases (n=284) were compared using the Mann-Whitney U-test for continuous 
variables and the two-tailed Fisher’s exact probability test for discrete variables. Also, in 
paper II, the 10-year probability of relapse (pRel) was calculated using the Kaplan-Meier 
method; only relapses were included in the estimations of cumulative incidence of relapse.  
The frequencies of specific CNAs in different cytogenetic subtypes described in paper III 
were compared using the two-tailed Fisher’s exact probability test for discrete variables. The 
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David Functional Annotation Bioinformatics tool (http://david.abcc.ncifcrf.gov) was used for 
gene cluster and pathway analyses in papers III and IV. 
In paper IV, statistic analyses were performed using R, and the statistical methods used for 
the genome and transcriptome analyses were implemented as described in the previous 
method sections. 
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4 RESULTS AND DISCUSSION 
4.1 FREQUENCY OF ∆IKZF1 IN NOPHO COHORTS 
In paper I, we investigated the frequency and prognostic impact of IKZF1 deletions 
(∆IKZF1) in patients diagnosed with ALL in the Stockholm region between 2001 and 2011; 
this was the first published study assessing the impact of ∆IKZF1 within the NOPHO 
protocols. Deletions were detected in 16% (19/116) of BCR/ABL1-negative BCP ALL cases; 
a minority (5/19) were intragenic deletions of exon 4-7, predicted to result in the dominant-
negative isoform IK6. Median WBC count in the group with ∆IKZF1 (n=19) and the group 
without ∆IKZF1 (n=97) was 20.3 and 8.1 respectively, which correlated with a slightly larger 
proportion of high-risk (HR) patients in the ∆IKZF1 group (21% vs. 15%).  
In paper II, the cohort was extended to include all BCR/ABL1-negative BCP ALL cases with 
available ∆IKZF1 data in Sweden (n=334). In this cohort, 15% (50/334) harbored deletions of 
the IKZF1 locus, a majority of these (58%) were focal (only including the IKZF1 gene) and 
there were no significant differences in clinical or molecular parameters between deletion 
types. Also in this study, the ∆IKZF1 -positive cases (n=50) had a significantly higher median 
WBC count than cases without ∆IKZF1 (n=284) and the ∆IKZF1 cases had more frequently 
been stratified as HR (36% vs. 14%; p<0.001).  
 
4.2 PROGNOSTIC IMPACT OF ∆IKZF1 IN NOPHO PROTOCOLS 
In paper I, we could show that the probability for event free survival (pEFS) and overall 
survival (pOS) were significantly reduced in the ∆IKZF1-positive group compared to the 
group with intact IKZF1 (p=0.02 and p=0.001, respectively) (Figure 4). These associations 
remained significant in a multivariate analysis adjusting for known clinical and molecular 
risk factors (pEFS; P=0.028, pOS; p=0.005), however MRD data was not available for the 
analysis. In addition, we observed a high prevalence of ∆IKZF1 (26%) in B-other cases, and 
∆IKZF1 was present in all cases that died in this group (4/34). Our results indicated that 
∆IKZF1 was an independent risk factor for poor outcome and that ∆IKZF1 might represent a 
negative prognostic marker for childhood leukemia treated accorded to NOPHO.  
The rationale for paper II was to further investigate the prognostic impact of ∆IKZF1 but 
also to determine if ∆IKZF1 is an independent risk factor also in the context of MRD and 
other prognostic markers. This study could confirm a significant association between ∆IKZF1 
and decreased pEFS (p<0.001) and pOS (p=0.001) as well as increased probability of relapse 
(pRel) (35% vs. 12%; p<0.001) (Figure 5) in the total cohort. However, the impact varied 
among the different NOPHO protocols and risk groups. ∆IKZF1-positive cases had a 
significantly increased pRel in the 1992 protocol but not in the 2000 and 2008 protocols 
(Figure 5). Also, ΔIKZF1 was associated with higher relapse rate in the SR and HR groups, 
but not in the IR group. Co-occurrence of ∆IKZF1 and PAR1 deletions (n=4) was 
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significantly associated with a higher risk of relapse compared to ∆IKZF1 without PAR1 
deletion (pRel 75% vs. 30%, p=0.045), while the presence of ERG deletions did not affect 
relapse risk for ∆IKZF1-positive cases (n=3). Multivariate analysis including the whole 
cohort showed that ∆IKZF1 was the strongest independent risk factor for relapse and poor 
outcome when age, WBC count, treatment protocol, MRD, PAR1 deletions and cytogenetic 
groups were included as variables in the model (p=0.001). This was true also when only 
patients with available MRD data (n=219) were included in the analyses.  
 
Figure 4 – Kaplan-Meier estimates of probability of A) event free and B) overall survival of B-cell precursor 
acute lymphoblastic leukemia cases (n=116) with and without IKZF1 deletions (blue and green lines 
respectively) treated according to NOPHO protocols in paper I 
 
Paper II could confirm that the frequency and prognostic effect of ∆IKZF1 was most 
pronounced in the B-other group; ΔIKZF1 was detected in 27% in this group and was 
strongly associated with increased risk of relapse (pRel 52% vs. 4%; p<0.001) (Figure 5) and 
decreased survival (pOS 58% vs. 90%; p<0.001). Notably, 83% of the relapsed B-other cases 
were ΔIKZF1-positive. The significant association with relapse risk and poor outcome in the 
B-other group was consistent through all three of the treatment protocols and remained 
significant in a multivariate analysis including only B-other.  
In an ongoing study, we are investigating the prognostic impact of ∆IKZF1 in approximately 
400 patients treated according to the current NOPHO-2008 protocol; preliminary data on 272 
cases show a potential significant association between ∆IKZF1 and relapse risk, as well as a 
high frequency (28%) of ∆IKZF1 in the B-other group (n=80), and a significant risk for 
relapse and poor outcome in this subtype.  
Taken together, these findings support that ∆IKZF1 represents a negative prognostic marker 
for childhood ALL treated according to NOPHO protocols, and highlight the importance of 
including ∆IKZF1 in the diagnostic evaluation of patients presently grouped as B-other.  
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Figure 5 – Kaplan-Meier estimates of probability of relapse of B-cell precursor acute lymphoblastic leukemia 
cases with and without IKZF1 deletions (blue and green lines respectively) A) in the total cohort (n=334), and B) 
in relation to treatment protocols, and C) in the B-other group (n=95) in paper II 
 
4.3 PAX5AMP – A NOVEL SUBTYPE OF ALL? 
An unexpected finding in paper I was a recurrent intragenic amplification of the PAX5 gene 
(PAX5AMP) in 4% (5/116) of the cohort. PAX5 encodes the transcription factor PAX5, an 
important regulator of B-cell development. The gene is frequently deleted or mutated in BCP 
ALL,84,98,136 however intragenic amplifications had previously only been reported in isolated 
cases,137,138 indicating that this aberration might escape detection using other methods than 
MLPA. The amplifications affected exons 2 and/or 5 (Figure 6), encoding the DNA-binding 
domains of PAX5. As all PAX5AMP cases were B-other and 40% (2/5) had relapsed, we 
proposed this as a potential novel genetic subtype of ALL.  
The frequency and prognostic impact of PAX5AMP were further explored in paper IX (under 
review in Blood), including MLPA data from 15 international study groups in Europe. 
Amplifications were validated using quantitative genomic PCR, arrays and FISH, and 
population-based screening showed that PAX5AMP occurred in ~1% of BCP ALL (52/5 535), 
with an incidence of 3% in the B-other group (33/1 271). PAX5AMP was associated with a 
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high risk for relapse, with 5-year event-free and overall survival rates of 49% (95% CI 36-
61%) and 67% (95% CI 54-77%), respectively. The amplifications remained stable between 
diagnosis and relapse, indicating that this abnormality might represent a primary event in 
ALL. The high incidence in B-other cases supports that PAX5AMP may define a distinct 
subtype that should be assessed as a potential risk-stratifying marker in future ALL protocols.  
 
 
Figure 6 – Images from MLPA analysis of one of the cases with PAX5AMP in paper I, the large peak in A and the 
high red probe marked with an arrow in B both correspond to amplification of PAX5 exon 5     
 
4.4 THE COPY NUMBER LANDSCAPE OF B-OTHER 
Cases without cytogenetic risk markers, i.e. B-other, constitute a diagnostic problem in all 
current treatment protocols, and the search for novel genetic markers is particularly relevant 
for this group. As described in previous sections, papers I and II demonstrated that ΔIKZF1 
is frequent in B-other cases and that the negative prognostic effect is particularly significant 
for this group. Also, papers I and IX have proposed PAX5AMP as a rare but recurrent negative 
prognostic marker for the B-other group. 
In paper III, where we investigated the CN landscape of ALL, ΔIKZF1 was detected in 35% 
of the B-other group; other frequent deletions affected VPREB1 (35%), CDKN2A/B (35%), 
PAX5 (20%) and ERG (15%). Deletions of the B-cell development gene VPREB1 
(ΔVPREB1) have recently been reported in association with poor prognosis90 and the 
Philadelphia-like subtype.98 While ΔIKZF1 consistently occurred together with other CNAs 
in our study, ΔVPREB1 was the only somatic imbalance detected in two B-other cases, 
suggesting that this deletion could be important for malignant transformation.  
Taken together, these four studies have shown that B-other cases harbor recurrent focal 
deletions with potential prognostic significance that are not detected and/or reported in the 
current genetic work-up of ALL. Detection of these deletions would provide information for 
risk stratification in NOPHO treatment protocols, particularly for the B-other group.  
 
PAX5 ex5 
A B 
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4.5 DELETIONS IN THE CYTOGENETIC SUBTYPES OF ALL  
According to the current view, most of the risk-stratifying genetic markers need secondary 
genetic alterations in order to cause leukemia. In paper II, we found no evidence for a 
prognostic impact of ΔIKZF1 in any of the cytogenetic subtypes except for B-other, and a 
negative correlation between t(12;21) and ΔIKZF1 was detected; only 6% of the cases with 
t(12;21) had ΔIKZF1. In paper III, we further characterized the genome-wide copy number 
landscape in different cytogenetic subtypes of BCP ALL. Overall, we identified over 400 
CNAs, and the vast majority of these lesions were subchromosomal deletions (Figure 7). The 
frequencies of recurrent CNAs in the different cytogenetic subtypes are shown in Figure 8; in 
agreement with previous studies, deletions of CDKN2A/B  (n=15), IKZF1 (n=15), VPREB1 
(n=15) and PAX5 (n=10) were common, but we also detected a few rare and recurrent 
deletions in genes not previously implicated in BCP ALL, including IRF1, PDE4B and INIP.  
 
 
Figure 7 – Ideogram summarizing somatic copy number alterations detected in paper III, with gains in green 
and losses in red 
 
IRF1 encodes a tumor suppressor protein involved in the regulation of normal hematopoiesis 
and leukemogenesis; deletions of IRF1 are frequent in myelodysplastic disorders139 and may 
thus constitute a possible mechanism of tumor suppression inactivation in ALL. 
Pharmacologic inhibition of PDE4B increases glucocorticoid sensitivity140 and constitutional 
variants have been associated with relapse in BCP ALL,141 which indicates that somatic loss 
of PDE4B could be relevant for therapy response and relapse in ALL. Deletion of the DNA 
repair gene INIP was unique for the t(12;21) subtype. The encoded protein is involved in the 
maintenance of genome stability and DNA damage response,142,143 and INIP deleted cases 
showed few additional CNAs, suggesting that this alteration could be important for leukemia 
development.  
Moreover, we found recurrent deletions recently described in association with high-risk and 
relapsed ALL that affected VPREB190 as well as the chromatin remodeling genes 
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CREBBP93,94,97 and TBL1XR1;95,96 the two latter are predicted to result in glucocorticoid 
resistance. CREBBP deletions (n=5) were exclusive to cases with polysomy of chromosome 
21, i.e. HeH and DS-ALL, and the HeH cases with focal CREBBP deletions had a positive 
MRD value at the end of induction. The presence of this high-risk alteration in the otherwise 
low-risk HeH subtype indicates a prognostic value in detecting and reporting this alteration in 
the clinical setting.97 Similarly, ΔVPREB1 was common in the t(12;21) group (55%) (Figure 
8) and associated with a higher WBC count in this otherwise low-risk subtype. Deletions of 
CREBBP and BTLA clustered in subtypes with extra chromosome 21 material, i.e. iAMP21, 
HeH, unbalanced t(12;21) and DS-ALL, suggesting that these deletions might be associated 
with both germline and somatic gain of chromosome 21 in BCP ALL.  
 
 
Figure 8 – Heat map showing relation between genes/regions affected by recurrent (>2 samples) CNAs (rows; 
red=deletion, green=duplication) and cytogenetic subtypes (columns) in paper III  
 
4.6 INTEGRATED ANALYSIS OF IAMP21 
Although the iAMP21 aberration only constitutes 2% of childhood BCP ALL, other 
alterations affecting chromosome 21, such as polysomies and translocations, are often seen in 
the disease. Moreover, iAMP21-positive BCP ALL is associated with a high risk of relapse 
when treated according to standard-risk protocols, and the biological mechanism behind the 
high relapse risk is still unknown.  
Papers I and II, which included 5 and 7 iAMP21 cases respectively, could show that 
ΔIKZF1 were infrequent in iAMP21 and did not add prognostic information for this subtype. 
In paper III, including three iAMP21 samples, a significant association between iAMP21 
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and deletions of the tumor suppressor gene RB1 and the JAK2 regulating gene SH2B3 
(p=0.001 and p<0.001 respectively) was detected. Also, the largest number of 
subchromosomal CNAs was found in the iAMP21 subtype, even after the 21q amplifications 
were excluded from the analysis (median 17, range 10–19). In paper IV, we further 
investigated the genomic structure and transcriptional effects of the iAMP21 rearrangement. 
SNP-array and WGS demonstrated a large complexity and heterogeneity of the iAMP21 
rearrangement between analyzed cases (Figure 9), however no obvious explanation to the 
pathogenicity could be found. The study could verify a high frequency of deletions in RB1 
(42%) and SH2B3 (42%), however none was present in all iAMP21 samples and thus the role 
of these CNAs in the pathogenicity of iAMP21 is not clear.  
 
 
Figure 9 – Circos plots of chromosome 21, showing A) CN data for all analyzed samples (n=12), and B) 
intrachromosomal rearrangements detected by mate-pair WGS (n=3); blue links represent rearrangements 
retaining the original strand orientation, red links represent inverted rearrangements, CN changes are shown with 
red (amplifications) and blue (deletions) lines in the circos edges 
 
To study the transcriptional effects underlying the pathogenicity of the 21q amplification, 12 
iAMP21-positive cases were compared with 34 iAMP21-negative BCP ALL cases using 
RNA sequencing. The analysis focused on the minimal region of amplification (MRA), 
determined by a previous study to a 5,1 Mb region on 21q22.3.69 Our results showed unique 
and significant overexpression of 13 MRA genes in iAMP21; the most significant of these 
were the tyrosine kinase gene DYRK1A and the chromatin remodeling genes CHAF1B and 
SON (Figure 10).  
 
A B 
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Figure 10 – Box plot showing mean expression of genes CHAF1B, DYRK1A and SON across the different 
subtypes of BCP-ALL in paper IV; these three genes were the top significantly overexpressed genes in the 
minimal region of amplification in the iAMP21 subtype 
 
Fusions including DYRK1A are present in BCP ALL,102 further strengthening the role of 
DYRK1A in this disease, and DYRK1A overexpression has been suggested as a potential 
tumor-promoting factor in Down syndrome associated ALL and acute megakaryocytic 
leukemia (AKML).144-146 DYRK1A promotes cell quiescence in normal lymphocyte 
development,147 and, interestingly, the cell quiescence mechanism of DYRK1A has been 
shown to cause relapses in gastrointestinal stromal tumors treated with Imatinib.148 Thus, the 
quiescence promoting function could be relevant for the relapse risk in patients with iAMP21, 
and the tyrosine kinase properties of DYRK1A makes it a potential candidate for targeted 
treatment.  
Both CHAF1B and SON are involved in chromatin remodeling. Overexpression of CHAF1B 
has been associated with unfavorable prognosis in several malignancies149-153 and short SON 
isoforms are upregulated in leukemic blasts and acute myeloid leukemia.154,155  
In paper IV, we also investigated the presence of sequence variants in the RNA sequencing 
data; many of the variants affected genes with cell cycle and/or kinase properties, and 
functional analysis demonstrated that all top significant clusters represented different aspects 
of cell division, including chromosome segregation, chromatin assembly and cell cycle 
regulation. However, no constitutional DNA was available for filtering of somatic variants, 
and thus it remains to be elucidated if the detected variants represent acquired mutations or 
constitutional variants with leukemia predisposing properties. 
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4.7 METHODOLOGICAL ASPECTS OF BCP ALL DIAGNOSTICS 
In paper I, we investigated the potential of MLPA as a method for targeted CN analysis. 
Comparison between FISH and MLPA results for alterations in CDKN2A and ETV6 showed 
a high concordance, with a slightly higher detection rate by MLPA. The likely explanation 
for this discrepancy is that the MLPA probes target smaller stretches of the genome and will 
thus detect CNAs below the resolution of FISH. The robustness of MLPA is affected by 
sample quality factors, in particular salt concentration, but with current DNA extraction 
methods and sufficient experience, the method had a high accuracy and low rate of false 
negative findings for CNAs present in >30% of cells. MLPA is inadequate to detect CNAs 
present in smaller subclones.  
In papers III and IV, we used array-CGH and SNP-array, respectively, to detect genome-
wide CNAs. Both methods have been validated in the clinical setting and array-CGH is now 
routinely used in the clinical diagnostics of childhood ALL at the Karolinska University 
Hospital. Both methods have a high sensitivity for detection of CNAs present in a majority of 
cells, however the array-CGH platform contains fewer probes, and thus CNAs affecting very 
small parts of the genome escape detection. For example, the PAX5AMP detected by MLPA in 
paper I was also detected by the SNP-array but not by array-CGH. Compared with MLPA, 
the SNP-array is more robust and can detect subclonal CNAs present in >20 % of cells, while 
the array-CGH has a low sensitivity for subclonal CNAs.  
To detect the novel prognostic CNAs in B-other cases, as well as the relapse-associated 
CNAs in standard-risk subtypes, high-resolution CN analysis at diagnosis is recommended. 
Importantly, relapse-prone alterations can be present in small subclones at diagnosis, and thus 
genomic array platforms used in the clinic should have a high probe density for the relevant 
genes, and ideally allow robust detection of small subclones.  
In paper IV, we used mate-pair WGS (MP-WGS) to investigate the iAMP21 subtype, and in 
paper VIII (submitted to Genes, chromosomes and cancer), this method was applied on BCP 
ALL cases with other cytogenetic alterations, i.e. t(1;19), t(9;22), t(12;21) and KMT2A 
rearrangement. Both studies showed that the method could detect structural rearrangements 
with high resolution. In paper VIII, MP-WGS accurately detected all known 
rearrangements, including determination of the exons involved and sometimes the exact 
fusion sequence, as well as previously undetected genetic events that could be confirmed by 
Sanger sequencing. The results indicate that MP-WGS combines the screening character of 
karyotyping together with the specificity and resolution offered by FISH and/or RT-PCR 
analysis. The WGS method offers large potential for leukemia diagnostics, however, the 
sequencing depth must be sufficient to detect subclonal alterations, and, ideally, information 
on constitutional variants should be used for filtering out somatic variants.   
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5 CONCLUSIONS 
In this thesis project, we have used a variety of methods to search for genetic alterations 
relevant for disease progression and outcome in childhood ALL. The main conclusions 
presented in this thesis are as follows: 
• IKZF1 deletion is a negative prognostic marker for childhood BCP ALL treated 
according to NOPHO protocols, with a pronounced effect in the B-other group 
• Intragenic amplifications of PAX5 might represent a novel genetic subtype associated 
with a high relapse risk in the B-other group  
• A majority of BCP ALL presently classified as B-other harbor recurrent focal CNAs 
with prognostic significance; screening for ΔIKZF1, PAX5AMP and PAR1 deletions at 
diagnosis would contribute to the diagnostic evaluation of these patients 
• CNAs associated with high relapse risk, i.e. deletions of CREBBP, VPREB1 and 
TBXLR1, are rare but recurrent in the low-risk cytogenetic subtypes, suggesting that 
detection of these would contribute to the clinical evaluation at diagnosis   
• Customized SNP-array platforms detect the novel prognostic CNAs with high 
accuracy, and MLPA represents a cost-effective alternative to this analysis. MP-WGS 
has the ability to detect both the current risk-stratifying alterations as well as the 
described novel CNAs in one single analysis  
• The iAMP21 subtype has a unique transcriptional profile, with significant 
overexpression of three potential candidate genes, i.e. the tyrosine kinase DYRK1A 
and the chromatin remodeling genes SON and CHAF1B; each of these genes is 
involved in leukemia development and could represent a potential target for therapy 
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6 FUTURE PERSPECTIVES 
While the novel markers proposed in this thesis are potential indicators of poor prognosis, no 
standardized treatment strategy is yet available for these cases. For example, relapses of 
ΔIKZF1-positive patients occur in all risk groups, including the HR group, which indicates 
that the currently used HR protocols are insufficient to prevent relapses for this subtype. 
Further insights into causative mechanisms behind the novel and currently used risk markers 
might open for targeted treatment approaches for these groups.  
The recent use of massively parallel sequencing methods in the research field has increased 
our knowledge of the molecular background in ALL. Rather than providing simple answers, 
studies have unveiled previously unknown complexities of the disease and revealed intricate 
correlations between constitutional and somatic genetic lesions, aberrant epigenetic patterns, 
transcriptional effects and treatment response. A better understanding of this interplay is 
likely needed in order to improve diagnostic and treatment procedures. Importantly, 
constitutional variants have been shown to play a role in therapy response and risk for therapy 
resistance and relapse. While the main focus of cancer diagnostics has been to find somatic 
drivers by filtering out constitutional variants, this new knowledge indicates that information 
on these variants might actually facilitate treatment decisions and help predict treatment 
response.  
Survival rates in modern protocols are approaching 90% and thus any change to the treatment 
approach must be carried out with precaution. Nevertheless, a reduction of treatment intensity 
would reduce the risk of side effects and improve quality of life for the patients. Further 
improvement of survival and quality of life in childhood ALL will likely be obtained through 
the development of targeted compounds combined with a more personalized diagnostic 
approach, where treatment decisions are based on the presence of targetable somatic 
mutations and therapy-relevant constitutional genetic variants in each child rather than on 
risk-group stratification.  
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